Single-cell analysis of bone marrow CD8[+] T cells in Myeloid Neoplasms predicts response to treatment with Azacitidine

Authors:

Athanasios Tasis[1,2], Nikos E. Papaioannou[3,*], Maria Grigoriou[1,4,*], Nikolaos Paschalidis[4,*], Katerina Loukogiannaki[4], Anastasia Filia[1,4], Kyriaki Katsiki[1], Eleftheria Lamprianidou[2], Vasileios Papadopoulos[2], Christina Maria Rimpa[1,2], Antonios Chatzigeorgiou[5], Ioannis P. Kourtzelis[6], Petroula Gerasimou[7], Ioannis Kyprianou[7], Paul Costeas[7], Panagiotis Liakopoulos[8], Konstantinos Liapis[2], Petros Kolovos[8], Triantafyllos Chavakis[9,10], Themis Alissafi[3,11], Ioannis Kotsianidis[2,*], Ioannis Mitroulis[1,2,9, 10,*,#]

Affiliations:

[1]Translational Research and Laboratory Medicine Unit, First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace; Alexandroupolis, Greece

[2]Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace; Alexandroupolis, Greece

[3]Laboratory of Immune Regulation, Center of Basic sciences, Biomedical Research Foundation Academy of Athens; Athens, Greece

[4]Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens; Athens, Greece

[5]Department of Physiology, Medical School, National and Kapodistrian University of Athens; Athens, Greece

[6]Hull York Medical School, York Biomedical Research Institute, University of York; York, United Kingdom

[7]Molecular Hematology-oncology, Karaiskakio Foundation, Nicosia, Cyprus

[8]Department of Molecular Biology and Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.

[9] Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of

Medicine Carl Gustav Carus of TU Dresden; Dresden, Germany

[10] National Center for Tumor Diseases, Partner Site Dresden, 01307 Dresden, Germany

[11] Laboratory of Biology, School of Medicine; Athens, Greece

* These authors contributed equally to this work

Corresponding author: Ioannis Mitroulis, MD, PhD, Email: imitroul@med.duth.gr

Running Title:

37 Single-cell analysis of CD8$^+$ T cells in MDS

Data Sharing Statement

39 The authors state that all data supporting this study are available in the main text or the

40 supplementary material. The raw scRNA-sequencing data for this study have been deposited in

41 the NCBI's Gene Expression Omnibus repository and are accessible through accession number

42 GSE250077. All other raw data can be provided by the authors upon reasonable request.

Key-points

45 • The frequency of bone marrow CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset predicts response to

46 azacitidine in MDS and AML patients.

47 • scRNA-seq analysis linked IFN pathway and TGF-β pathway signature in CD8$^+$ T cells

48 with response and failure to treatment, respectively.

Abstract

Treatment with hypomethylating agents (HMA), and specifically azacitidine (AZA), is the standard of care for patients with higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) that are not eligible to receive intensive chemotherapy. Despite research efforts, it is not possible to predict response to treatment with HMA. In this study, we aimed to identify immune cell signatures in the bone marrow (BM) associated with treatment outcomes. By employing mass cytometry, we performed an in-depth immunophenotypic analysis in BM samples deriving from patients with myeloid neoplasms prior to treatment initiation. We identified an increased pre-treatment frequency of a $CD8^+$ T cell subset, characterized as $CD57^+CXCR3^+CCR7^-CD45RA^+$, in patients with MDS and AML who did not respond to treatment with AZA, compared to responders. Furthermore, an increased baseline frequency ($>29\%$) of $CD57^+CXCR3^+CD8^+$ T cells was correlated with poor overall survival. We further engaged scRNA-seq to assess the transcriptional profile of BM $CD8^+$ T cells from treatment-naïve patients with MDS and AML, to identify molecular signatures in $CD8^+$ T subpopulations associated with favorable outcomes. Response to treatment was positively associated with enrichment of IFN-mediated pathways coupled with enhanced cytotoxic signature, whereas enrichment of the TGF-β signaling pathway was observed in cell clusters from non-responders. Together, this study identified a specific $CD57^+CXCR3^+CD8^+$ T cell population with predictive value in patients with MDS and AML treated with AZA and characterized molecular signatures in $CD8^+$ T cells linked to cytokine signaling that were associated with treatment outcomes.

Main Text:

INTRODUCTION

Myeloid neoplasms encompass a diverse group of clonal disorders, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), which share common features in their pathobiology.[1] While genetic alterations and epigenetic modifications play a role in the development of myeloid neoplasms, the interaction between clonal and immune cells is crucial.[2–5] Despite being clonal diseases originating from hematopoietic stem cell progenitors, there is compelling evidence from human and animal studies indicating that the interplay between clonal cells and the bone marrow (BM) microenvironment plays a significant role in the development and progression of MDS and CMML.[6–12]

T lymphocytes, and especially CD8$^+$ T cells play, a crucial role in the regulation of tumor microenvironment.[13] Aberrant functionality of CD8$^+$ T cells has been observed in patients with myeloid neoplasms compared to healthy individuals.[14,15] The impaired functionality of CD8$^+$ T lymphocytes within the tumor microenvironment constitutes an important target for immunotherapeutic interventions.[16–21] Nevertheless, the role of T cells in disease progression and response to treatment in myeloid neoplasms remains largely unknown.

To date, the most utilized tool for the stratification of MDS patients into risk groups is the Revised International Prognostic Scoring System (IPSS-R), based on clinical and laboratory parameters.[22] The recently developed Molecular IPSS (IPSS-M) includes also mutational data.[23] The standard of care for patients with higher-risk MDS (HR-MDS) and non-proliferating CMML, as well as patients with secondary AML, who are not eligible for intensive chemotherapy, is treatment with hypomethylating agents (HMA) like azacitidine (AZA).[24–27]

However, not all patients exhibit a favorable response, and there is a significant risk of

relapse.[28,29] Additionally, molecular predictors of response to HMA and the precise mechanism

of action of this drug are not well-defined. The exact genetic and cellular processes through

which HMA exerts its effects are still being studied,[30] whereas there are no therapeutic

approaches to overcome resistance to this treatment.[31]

To address whether immune cells in the BM play a role in disease progression of myeloid

neoplasms and in the prediction of the response to treatment, we engaged a systematic approach

to study the immune landscape of BM samples from patients with myeloid neoplasms prior to

treatment initiation. We performed mass cytometry (CyTOF) for the immunophenotypic

characterization of immune cell populations in the BM. Based on this analysis, we then focused

on CD8[+] T cells and performed single-cell RNA sequencing (scRNA-seq), to address the

molecular signature in CD8[+] T cell subsets that are linked to response to treatment with AZA.

MATERIALS AND METHODS

A comprehensive description of the methods is given in supplemental Methods.

Study patients

BM samples were collected from patients with lower-risk (LR)-MDS, HR-MDS (subtypes Increased Blasts (IB)1 and IB2), AML and CMML-2 before treatment initiation. Detailed demographic and clinical data are presented in Table 1. The study was approved by the Ethics Committee of the University Hospital of Alexandroupolis, under the reference number (877/23-10-2019). All patients provided informed written consent in accordance with the principles outlined in the Declaration of Helsinki.

Mass cytometry and data analysis

High-dimensional immunophenotyping of bone marrow mononuclear cells (BMMCs) was performed with mass cytometry using established and validated workflows from previous studies.[32,33] We employed the Maxpar Direct Immune Profiling Assay (MDIPA) (Standard Biotools) (Supplemental Table 1).[34] Acquisition was performed using a Helios™ system. Data analysis was performed on CD45$^+$ cells. FlowSOM clustering analysis and dimensionality reduction via tSNE were carried out in the R programming environment (version 4.1.0), as previously described.[33] For targeted analysis of T cell populations, Cytobank was used.

scRNA-seq and data processing

Sorted cells were resuspended, combined by three per well of the Chromium Next GEM Chip G

(10X Genomics) and loaded onto the Chromium Controller (10X Genomics). Samples were

processed for single-cell encapsulation, cDNA and cell multiplexing library generation using the

Chromium Next GEM Single Cell 3□ Reagent Kits v3.1 (Dual Index) (10X Genomics). The

constructed libraries were sequenced on an NovaSeq 6000 sequencer. The 10X Genomics Cell

Ranger multi v7.1.0 pipeline, was used to map the sequencing reads to the human genome

(GRCh38) and generate the gene expression and feature barcode matrices.

RESULTS

Immunophenotypic analysis of BM immune cell populations

To study the immune cell compartment, we performed deep immunophenotyping using CyTOF

in BM samples from patients with LR-MDS, HR-MDS, AML and CMML collected before

treatment initiation. Multidimensional scaling analysis revealed a separation of samples derived

from patients with MDS and AML compared to CMML based on dimension 2 (Figure 1A).

Untargeted cluster analysis resulted in the identification of 14 clusters of cells (Figure 1B-C). We

observed a significantly decreased frequency of cells in the cluster of CD4$^+$ T cells (CD4 T1) and

B cells in patients with CMML, with a respective increase in the frequency of monocytic cells of

myeloid cluster 2, characterized by the expression of CD11c, CD14 and CD38 (Figure 1D). We

further evaluated the expression of the chemokine receptors C-C chemokine receptor 4 (CCR4),

CCR6, CCR7 and C-X-C Motif Chemokine Receptor 3 (CXCR3), CD161 and CD294 within the

T cell clusters (Supplemental Figure 1). We observed increased expression of CXCR3 on cells

from patients with AML and CMML compared to MDS patients in the CD4 T2, CD8 T1 and

CD8 T2 clusters (Figure 1E).

Based on these findings, we then focused on $CD4^+$ and $CD8^+$ T cells and performed an

untargeted cluster analysis on $CD3^+CD4^-CD8^+$ (Figure 2) and $CD3^+CD4^+CD8^-$ T cells

(Supplemental Figure 2). We identified 10 clusters of $CD8^+$ T cells (Figure 2A). We observed a

significant decreased frequency of cells within cluster 1 in samples from patients with LR-MDS

and HR-MDS compared to AML and CMML (Figure 2B), which included terminal effector cells

($CCR7^-CD45RA^+$), expressing CD57 and CXCR3 (Figure 2C). We also identified an additional

cluster (cluster 2) of terminal effector cells ($CCR7^-CD45RA^+$), that did not express CD57 and

CXCR3, and did not show any difference among the groups (Figure 2B-C). Additionally, the

expression of CXCR3 within cluster 1 was higher in cells from patients with AML and CMML

compared to patients with HR-MDS (Figure 2D). Similar analysis on $CD4^+$ T cells did not reveal

any difference in the frequency of the generated clusters (Supplemental Figure 2).

Based on these findings, we further engaged flow cytometry in BM cells from an additional

cohort of patients, focusing on the frequency of $CD3^+CD8^+CD57^+CXCR3^+$ T cells (Figure 2E-

F). We included samples from eight patients that were also analyzed with CyTOF, to compare

the two methods. We observed that the frequency of this cell population within $CD8^+$ T cells was

increased in patients with AML and CMML compared to LR- and HR-MDS (Figure 2F), being

in line with the findings from the unsupervised analysis of data derived from CyTOF.

The proportion of $CD57^+CXCR3^+$ $CD8^+$ T cells is associated with the response to AZA

We next assessed whether the proportion of CD57$^+$CXCR3$^+$ within the CD8$^+$ T cell population

before treatment initiation with HMA was associated with response to treatment. Univariate

analysis revealed that a decreased percentage of CD57$^+$CXCR3$^+$ CD8$^+$ T cells is associated with

better response (Supplemental Table 2). The frequency of this cell subset was significantly

increased in patients with HR-MDS and AML that did not respond to treatment, whereas no

difference was observed in patients with CMML (Figure 3A). Next, utilizing the CyTOF data,

we performed unsupervised cluster analysis of CD3$^+$CD4$^-$CD8$^+$ T cells in responders and non-

responders to AZA patients with MDS and AML, which resulted in the identification of 6 cell

clusters (Figure 3B). We observed an increased frequency of cluster 3 in non-responders (Figure

3B and D), a cluster of CCR7$^-$CD45RA$^+$ effector cells characterized by the expression of CD57

and CXCR3 (Figure 3C). Conversely, we observed an increased frequency of cluster 6 in

responders, characterized by naive/memory markers CD28, CD27, CCR7, CD127 (Figure 3C-

D). On the other hand, there was no difference between responders and non-responders in the

analysis of CD3$^+$CD8$^-$CD4$^+$ T cells (Supplemental Figure 3).

We further evaluated whether the frequency of the CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset was

associated with survival. To do so, optimal CD57$^+$CXCR3$^+$ cut-off was determined at >29% by

transformation of scale variable to binary one through optimal scaling. We observed that patients

with ≤29% CD57$^+$CXCR3$^+$ CD8$^+$ T cells had better overall survival (OS) (Figure 3E). When

patients with HR-MDS, AML and CMML were evaluated separately, we observed that this cut-

off value could be applied to patients with HR-MDS and AML but not to patients with CMML

(Figure 3F). Thereafter, we aimed to assess the applicability of this cut-off in predicting response

to treatment with AZA. Patients with HR-MDS and AML and ≤29% CD57$^+$CXCR3$^+$ CD8$^+$ T

cells demonstrated higher rates of response to AZA (Figure 3G). In contrast, the percentage of

CD57$^+$CXCR3$^+$ CD8$^+$ T cells was not associated with response to treatment in patients with

CMML (Figure 3G). Together, these findings suggest that an increased frequency of the

CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset is associated with treatment failure and worse survival in

patients with MDS and AML treated with AZA.

193   Association between mutational status and frequency of CD57$^+$CXCR3$^+$ CD8$^+$ T cells

We further investigated whether there is a connection between mutational burden, type of

mutations, and the frequency of CD57$^+$CXCR3$^+$ CD8$^+$ T cells. No difference was found in the

frequency of this cell population when patients were categorized based on the oncogenic

mutations (Supplemental Figure 4A), whereas no single mutation was associated with an

increased frequency (>29%) of the CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset (Supplemental Figure

4B). Furthermore, the number of oncogenic mutations was not significantly altered in patients

with >29% CD57$^+$CXCR3$^+$ CD8$^+$ T cells compared to patients with a lower frequency (≤29%)

(Supplemental Figure 4C), and no specific group of oncogenic mutations was associated with the

frequency of CD57$^+$CXCR3$^+$ T cells (Supplemental Figure 4D).

203   Single-cell transcriptomes of CD8$^+$ T cells are associated with treatment outcome

We next sought to assess the molecular signature of BM CD8$^+$ T cells from patients with MDS

and AML at the single cell level, to identify molecular signatures in specific CD8$^+$ T cell

subpopulations associated with a favorable outcome. scRNA-seq was performed in sorted BM

CD8$^+$ T cells from patients with HR-MDS (n=4) and AML (n=5). We obtained transcriptomes of

28,449 cells in total. Based on unsupervised clustering, cells were partitioned in 11 clusters

(Figure 4A), which were characterized according to the gene expression of markers associated

with T cell phenotype,[35] including naive/memory markers (*CCR7*, *IL7R*, *SELL*, *CD27*, *CD28*,

CD44), cytotoxic markers (*GZMA*, *GZMB*, *GZMK*, *PRF1*, *CX3CR1*, *NKG7*, *HOPX*, *KLRG1)*,

cell cycle genes (*MKI67*, *CCNB2)*, the transcription factors (TFs) *LEF1*, *EOMES* and *TCF7*, the

cytokine *IFNG*, and the cell surface markers *ITGA1*, *CD69* and *CCR6* (Figure 4B-C). We

identified clusters of cells characterized by the expression of *GZMK* (cluster 0), and *EOMES*,

KLRG1 and *GZMK* (cluster 1), previously characterized as pre-dysfunctional.[35,36] We further

identified two clusters of cytotoxic CD8[+] T lymphocytes, clusters 2 (CTL_1) and 4 (CTL_2),

based on the expression of *GZMA*, *GZMB* and *PRF1*.[37] Clusters 1, 2 and 4 were the clusters with

the highest frequency of cells expressing *B3GAT1*, the gene that encodes CD57 (Supplemental

Figure 5). We identified a cluster of memory-like cells, characterized by the expression of *IL7R*

and low expression of *CCR7*, *SELL*, *CD27* (cluster 3), a cluster of naive-like cells, expressing

CCR7, *SELL*, *CD27* and the TFs *TCF7* and *LEF1*[38] (cluster 5), a cluster characterized by the

expression of *CCR6* (cluster 6) and a cluster characterized by the highest expression of *CD44*

(cluster 7) (Figure 4B-C). Cluster 8 included cells expressing *ITGA1* and *ITGAE* (Figure 4D),

previously described as resident memory cells (cluster 8),[38–40] and cluster 9 included cytotoxic

cells expressing *IFNG*, *GZMK* and *NKG7*. We did not observe significant expression of genes

associated with exhaustion, such as *PDCD1*, *LAG3*, *HAVCR2*, *ENTPD1* or *CTLA4*[35] or a cluster

of cells characterized by the expression of such genes (Figure 4B; Supplemental Figure 6).

Finally, a cluster of proliferating T cells (cluster 10) was identified (Figure 4B-C). Top

differentially expressed genes (DEGs) for each cell cluster are depicted in Figure 4D. We further

engaged a previously reported cytotoxic score[41] to confirm the enhanced cytotoxicity of cells in

clusters 2 (CTL_1), 4 (CTL_2) and 9 (*IFNG*) (Figure 4E) and a cell cycle score[41] to confirm the

increased proliferation activity of cells in cluster 10 (Proliferative) (Figure 4F). We next

investigated the trajectories that cells traverse during T cell differentiation, using naïve-like cells (cluster 5), as a starting point (Figure 4G). Based on this analysis, we observed that cells from clusters 1 (*EOMES*), 2 (CTL_1) and 7 (*CD44)* are composed of cells most differentiated cells (Figure 4G). Regarding the trajectories that lead to these clusters, we identified one trajectory that derives from cluster 0 (*GZMK*) and leads to clusters 2 (CTL_1) and 7 (*CD44)* through cluster 1 (*EOMES*) and two other trajectories that derive from cluster 0 (*GZMK*) and lead to 2 (CTL_1) through cluster 4 (CTL_2) (Figure 4G).

Single-cell transcriptomes of CD8[+] T cells are associated with treatment outcome

We next sought to investigate the molecular signatures in CD8[+] T cell subpopulations associated with response to AZA (Figure 5A). We did not observe any statistically significant difference in the cluster abundance in patients that achieved complete remission (CR) after treatment with AZA (n=2 patients with HR-MDS, 7,571 cells; n=2 patients with AML, 6,096 cells) and patients that failed (FAIL) to treatment (n=2 patients with HR-MDS, 8,026 cells; n=3 patients with AML, 6,756 cells) (Figure 5B), except from an increased abundancy of cluster 10 (Proliferative) in the CR group (Supplemental Figure 7).

Pathway analysis was performed, and DEGs upregulated in the CR group were associated with IFN response in all clusters (Figure 5C). To this direction, increased expression of the IFN-responsive genes *MT2A*, *BST2*, *STAT1* and *IRF2* was observed in the CR group (Figure 5D). We then focused on specific clusters, and we used a score that derives from the expression of interferon stimulated genes (ISG signature).[42] We observed higher ISG signature score in the CR group in cluster 0 (*GZMK*), which was associated with increased expression of the IFN-responsive genes *CCL5*, *MT2A*, *BST2*, *CD74*, *GZMA*, *PSME1*, *PSME2*, *CD69*, *VAMP8* and

TXNIP (Figure 5E). Similarly, increased expression of *HLA-DRB1*, *MT2A*, *BST2*, *CD74*, *TXNIP*,

GZMA, *PSME1*, *PSME2*, *CD69*, *PTPN2*, *IRF2*, *STAT1*, *SOCS1* and *KLRK1* was observed in

cluster 1 (*EOMES*) (Figure 5F). Regarding the cytotoxic clusters 2 (CTL_1) (Figure 5G;

Supplemental Figure 8A) and 4 (CTL_2) (Figure 5H; Supplemental Figure 8B), higher ISG

signature and increased expression of the genes *IFITM2*, *MT2A*, *BST2*, *STAT1*, *GZMA*, *PSME1*,

PSME2 and *CD69* was detected in cells from the CR group from both clusters.

Pathway analysis of DEGs upregulated in the FAIL group demonstrated that cells from the

clusters 0 (*GZMK*), 1 (*EOMES*), 2 (CTL_1), 3 (Memory), 4 (CTL_2), 5 (Naïve), 6 (*CCR6*) and 8

(Trm) were enriched for DEGs associated with TNF signaling (Figure 6A; Supplemental Figure

9). Moreover, cells from the cytotoxic clusters 2 (CTL_1), 4 (CTL_2), 9 (*IFNG*) and clusters 3

(Memory), 6 (*CCR6*) and 7 (*CD44*) were enriched for DEGs of the TGF-β signaling pathway

(Figure 6A). Specifically for cluster 2 (CTL_1), there was higher TGF-β signature score in the

FAIL group and increased expression of *TFGB1*, *SMURF2*, *SMAD7*, *SKI*, *SKIL* (Figure 6B;

Supplemental Figure 8A), whereas for cluster 4 (CTL_2) the higher TGF-β signature score was

associated with increased expression of *TFGB1*, *ARID4B*, *SMAD7*, *SKI*, *SKIL* and *SMURF2*

(Figure 6C; Supplemental Figure 8B). Since TGF-β signaling has been previously associated

with decreased cytotoxicity,[43] we further used the cytotoxic signature score (Figure 6D) to

address whether the TGF-β signature is associated with decreased cytotoxic activity in CTL

clusters in the FAIL group. We observed higher cytotoxic score in the CR group in cluster 2

(CTL_1), which was associated with the enhanced expression of *GZMA*, *GZMB*, *CX3CR1* and

CCND3 (Figure 6E) and in cluster 4 (CTL_2), which was associated with enhanced expression

of *FGFBP2*, *GZMA*, *GZMB*, *GZMH*, *CCND3*, *C1orf162* and *CX3CR1* (Figure 6F).

Cytokines act together with transcription factors (TFs) to regulate T cell fate and functionality.[44]

To study the TFs that could act as possible regulators of the transcriptomic alterations observed

in responders to AZA compared to non-responders, TF regulatory network analysis was

performed using SCENIC,[45] which resulted in the identification of 11 clusters-regulons (Figure

7A). We observed that regulon 5 was enriched with cells from the CR group of patients, whereas

regulon 7 was enriched with cells from the FAIL group (Figure 7B-C). Regulon cluster 5 was

characterized by IRF7-, CHURC1-, NFYB- and RFXANK-regulated networks (Figure 7D) and

was enriched mainly with cells from cluster 4 (CTL_2) (Supplemental Figure 10). On the other

hand, regulon 7 was characterized by the NFKB2-, REL-, RELB-, CREM- and NFKB1-

regulated networks (Figure 7D) and it was enriched with cells from cluster 0 (*GZMK*) and cluster

1 (*EOMES*) (Supplemental Figure 10), previously described as pre-dysfunctional cells.[35,36]

Differential TF activity analysis between the two groups of patients within regulon 5, predicted

that the activity of the TFs IRF2, IRF9 and STAT1 was increased in the CR group and the

activity of RELB, REL, NFKB2, NFKB1 and SMAD3 was increased in the FAIL group (Figure

7E). Similar analysis within regulon 7, predicted increased activity for IRF2 and STAT1 and

decreased activity for NFKB1 in cells derived from the CR group (Figure 7F). Taken together,

the TF regulatory network analysis further supports that BM CD8$^+$ T cells in the CR group are

targeted by TFs associated with IFN signaling, whereas TFs linked to TGF-β and TNF signaling

target CD8$^+$ T cells in the FAIL group.

DISCUSSION

Herein, we provide a systemic analysis at the single cell level of CD8$^+$ T cells derived from the BM immune microenvironment of patients with myeloid neoplasia. We specifically focused on the identification of specific immunophenotypic, and molecular signatures associated with the outcome of AZA treatment.

Deep immunophenotyping with CyTOF demonstrated that patients with HR-MDS and AML who did not respond to treatment with AZA exhibited increased pre-treatment levels of the CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset compared to responders, while a frequency of CD57$^+$CXCR3$^+$ CD8$^+$ T cells of more than 29% prior to initiation of treatment was associated with worse OS. Hence, our findings demonstrate a significant correlation between elevated pre-treatment frequencies of the CD57$^+$CXCR3$^+$ CD8$^+$ T cell subset and unfavorable outcome in patients with HR-MDS and AML under treatment with AZA.

The expression of CD57 by CD8$^+$ T cells, coupled with the absence of CD28 expression, characterizes a senescent-like phenotype, linked to chronic immune activation in several disorders.[46–49] These CD57$^+$CD28$^-$ CD8$^+$ T cells are antigen specific effector cells that have limited proliferation capacity, due to their advanced differentiation stage.[50,51] Previous studies demonstrated increased levels of CD57$^+$CD28$^-$ CD8$^+$ T cells in patients with MDS and AML compared to healthy individuals.[15,52] CXCR3, on the other hand, is expressed on Th1-CD4$^+$ T cells[53] and effector CD8$^+$ T cells[54] and is considered crucial for the recruitment of T cells to inflammatory sites.[54–56] The expression of CXCR3 on CD8$^+$ T cells has been associated with changes in the equilibrium from memory towards effector cell populations.[57,58] Interestingly, recent studies engaging scRNA-seq in CD8$^+$ T cells isolated from patients with cancer have described cells expressing *CXCR3* together with *GZMK* and *EOMES* as a pre-dysfunctional cell

population.[36,59] In this study, we demonstrate for the first time that enhanced frequency of the

CD8$^+$ T subset CD57$^+$CXCR3$^+$ is linked to adverse outcomes in patients with HR-MDS and

AML treated with AZA.

Recent findings indicate that the immune system, specifically CD4$^+$ and CD8$^+$ T cells, is affected

and plays a critical role in the response to AZA,[60–62] a DNA hypomethylating agent which has

emerged as a standard treatment option for patients who are ineligible for intensive

chemotherapy.[63–65] In this study, we observed that patients that did not respond to AZA treatment

were characterized by increased levels of a CD57$^+$CXCR3$^+$ CD8$^+$ T cells, prior to the initiation

of AZA treatment. It has been recently demonstrated that the accumulation of senescent-like

CD8$^+$CD57$^+$ T cells is negatively associated with the response to chemotherapy and checkpoint

blockade immunotherapy in AML patients.[66] Interestingly, utilizing *in vitro* studies, it was

shown that patient-derived senescent-like T cells were not able to sufficiently eliminate

autologous AML-blasts when compared to their non-senescent CD8$^+$ T cell counterparts,

providing evidence for their limited ability to clear leukemic cells.[66] To the same direction, we

demonstrate that increased pre-treatment frequency of BM CD57$^+$CXCR3$^+$ CD8$^+$ T cells is

associated with poor OS and response to AZA treatment.

Based on our findings from immunophenotyping, we engaged scRNA-seq analysis to investigate

CD8$^+$ T cells from responders and non-responders to AZA treatment. A significant enrichment of

the TGF-β signaling pathway was observed in cytotoxic clusters (CTL_1 and CTL_2) of non-

responders. This pathway has been associated with suppression of cytotoxicity, tumor evasion

and poor outcomes.[67] In line with this, non-responders displayed decreased cytotoxic signature

within the same clusters. Interestingly, Luspatercept, a TGF-β inhibitor, has been approved by

the FDA as a line of treatment for patients with anemia and lower-risk myelodysplastic

syndromes with ring sideroblasts.[68,69] Studies have shown that Luspatercept can sufficiently

stimulate erythropoiesis resulting in transfusion independence, while also significantly extending

the time to AML progression.[70] To this direction, it could be worthwhile considering the

potential benefits of combined treatment with AZA and TGF-β inhibitors for patients with HR-

MDS and AML.

On the other hand, responders exhibited a significant enrichment of pathways associated with

IFN response, across many BM CD8$^+$ T cell clusters. Type I and II Interferons play a crucial role

in immune activation during anti-tumor responses.[71–73] Notably, there is evidence indicating that

AZA exerts its effects in an IFN-dependent manner by increasing the production of IFN-γ,[74]

activating type I Interferon signaling,[75–77] as well as upregulating the expression of Interferon

Stimulated Genes (ISGs), all of which aid in the rejuvenation of the anti-tumor immunity.[77,78]

Taken together, our findings suggest that the balance between TGF-β and IFN signaling in CTLs

within the BM microenvironment may regulate their anti-tumor effect, affecting the response to

treatment.

Immunotherapies based on immune checkpoint blockade (ICB) have revolutionized the field of

oncology, especially in the case of solid tumors.[79–82] Many studies employing scRNA-seq in

solid tumors demonstrated that CD8$^+$ T cells show a distinct molecular signature, indicative of an

exhausted phenotype, which is associated with disease progression and treatment resistance,[41,83–

85] thereby providing evidence supporting the effectiveness of ICB treatment in these patients. In

contrast, ICB therapy in myeloid malignancies, including MDS and AML, has yielded limited

results so far, while the risk of serious adverse events still remains.[86,87] Notably, our scRNA-seq

analysis did not reveal any distinct CD8$^+$ T cell clusters with expression of genes related to a

dysfunctional/exhausted molecular signature. These findings support the clinical observations

that ICB treatment might not be the optimal option for HR-MDS and AML treatment.

Taken together, this study provides important insights on the specific phenotypes and molecular

signatures associated with effector T cell functionality of BM CD8$^+$ T cells that can inform

prognosis in MDS and AML patients treated with AZA. To our knowledge, we studied for the

first time, at the single cell level, the association between BM CD8$^+$ T cells and the outcome of

AZA treatment in primary human samples of patients with myeloid neoplasia. Prospective

studies in large cohorts are needed to evaluate whether the relative frequency of CD8$^+$ T cell

subpopulations could be used in the prognostication of patients with myeloid neoplasms treated

with hypomethylating agents.

Funding:

This study was supported by the Hellenic Foundation for Research and Innovation (HFRI) under the HFRI "Research Projects to Support Faculty Members & Researchers and Procure High-Value Research Equipment" grant (HFRI-FM17-452) and the General Secretariat for Research and Technology Management and Implementation Authority for Research, Technological Development, and Innovation Actions (MIA-RTDI) (grant T2EDK-02288, MDS-TARGET). TA and NEP are supported by the ERC under the European Union's Horizon 2020 research and innovation program (grant agreement no 947975 to T. Alissafi) and from the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the "2nd Call for H.F.R.I. Research Projects to support Post-Doctoral Researchers" (Project Number: 166 to T. Alissafi) and the "Sub-action 1. Funding New Researchers – RRF: Basic Research Financing (Horizontal support for all Sciences) (Project number: 15014 to T. Alissafi). IPK is funded by the Academy of Medical Sciences (R2429101) and Rosetrees Trust (R2449101). TC is supported by the Deutsche Forschungsgemeinschaft (TRR332, project B4).

Authorship Contributions:

Conceptualization: AT, IK, IM

Methodology: AT, MG, NEP, NP, PC, TC, TA, IM

Investigation: AT, MG, KLO, AF, KK, EL, VP, AC, IPK, PG, PK, PL, IKY, KL

Visualization: AT, NEP, NP

Funding acquisition: IPK, TC, TA, IM

396   Project administration: IM

397   Supervision: IM

398   Writing – original draft: AT, IM

399   Writing – review & editing: AT, IPK, TC, IK, IM

401   **Competing interests:** Authors declare that they have no competing interests.

References

1. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200–1228.

2. Ogawa S. Genetics of MDS. *Blood*. 2019;133(10):1049–1059.

3. Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. *Leukemia*. 2014;28(3):497–506.

4. Fozza C, Crobu V, Isoni MA, Dore F. The immune landscape of myelodysplastic syndromes. *Crit Rev Oncol Hematol*. 2016;107:90–99.

5. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. *Blood*. 2012;120(10):2076–2086.

6. Balderman SR, Li AJ, Hoffman CM, et al. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. *Blood*. 2016;127(5):616–625.

7. Kitagawa M, Yamaguchi S, Takahashi M, et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. *Leukemia*. 1998;12(4):486–492.

8. Ferrer RA, Wobus M, List C, et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. *Haematologica*. 2013;98(11):1677–1685.

9. Sarhan D, Wang J, Sunil Arvindam U, et al. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. *JCI Insight*. 2020;5(5):130155.

10. Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth

factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. *Br J*

Haematol. 2002;118(1):151–156.

11. Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. *Blood*. 2019;133(10):1031–

1038.

12. Chavakis T, Wielockx B, Hajishengallis G. Inflammatory Modulation of Hematopoiesis:

Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders. *Annual*

Review of Physiology. 2022;84(1):183–207.

13. Verma NK, Wong BHS, Poh ZS, et al. Obstacles for T-lymphocytes in the tumour

microenvironment: Therapeutic challenges, advances and opportunities beyond immune

checkpoint. *EBioMedicine*. 2022;83:104216.

14. Knaus HA, Berglund S, Hackl H, et al. Signatures of CD8+ T cell dysfunction in AML

patients and their reversibility with response to chemotherapy. *JCI Insight*.

2018;3(21):120974.

15. Radpour R, Riether C, Simillion C, et al. CD8+ T cells expand stem and progenitor cells in

favorable but not adverse risk acute myeloid leukemia. *Leukemia*. 2019;33(10):2379–2392.

16. Liu X, Hoft DF, Peng G. Senescent T cells within suppressive tumor microenvironments:

emerging target for tumor immunotherapy. *J Clin Invest*. 130(3):1073–1083.

17. Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer

immunotherapy: A review. *J Cell Physiol*. 2019;234(6):8509–8521.

18. Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and

cancer immunotherapy. *Br J Cancer*. 2021;124(2):359–367.

19. Huang Y, Jia A, Wang Y, Liu G. CD8+ T cell exhaustion in anti-tumour immunity: The new

insights for cancer immunotherapy. *Immunology*. 2023;168(1):30–48.

20. Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting

therapy. *J Hematol Oncol*. 2023;16(1):38.

21. Zhang J, He T, Xue L, Guo H. Senescent T cells: a potential biomarker and target for cancer

therapy. *EBioMedicine*. 2021;68:103409.

22. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System

for Myelodysplastic Syndromes. *Blood*. 2012;120(12):2454–2465.

23. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring

System for Myelodysplastic Syndromes. *NEJM Evidence*. 2022;1(7):EVIDoa2200008.

24. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic

leukemia. *Cancer*. 2011;117(12):2690–2696.

25. Platzbecker U, Fenaux P. Recent frustration and innovation in myelodysplastic syndrome.

Haematologica. 2016;101(8):891–893.

26. Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic

syndromes and acute myeloid leukemia: Past discoveries and future directions. *Am J*

Hematol. 2022;97(12):1616–1626.

27. Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the

treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of

resistance and novel HMA-based therapies. *Leukemia*. 2021;35(7):1873–1889.

28. Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models

in predicting outcome of patients with myelodysplastic syndromes at the time of

hypomethylating agent failure. *Haematologica*. 2016;101(6):e224-227.

29. Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after

azacitidine treatment failure. *J Clin Oncol*. 2011;29(24):3322–3327.

30. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in

myelodysplastic syndromes. *J Clin Oncol*. 2011;29(5):516–523.

31. Zhao G, Wang Q, Li S, Wang X. Resistance to Hypomethylating Agents in Myelodysplastic

Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.

Front Oncol. 2021;11:706030.

32. Vakrakou AG, Paschalidis N, Pavlos E, et al. Specific myeloid signatures in peripheral blood

differentiate active and rare clinical phenotypes of multiple sclerosis. *Front Immunol*.

2023;14:1071623.

33. Nowicka M, Krieg C, Crowell HL, et al. CyTOF workflow: differential discovery in high-

throughput high-dimensional cytometry datasets. *F1000Res*. 2017;6:748.

34. Bagwell CB, Hunsberger B, Hill B, et al. Multi-site reproducibility of a human

immunophenotyping assay in whole blood and peripheral blood mononuclear cells

preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data

analysis system. *Cytometry B Clin Cytom*. 2020;98(2):146–160.

35. van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human cancer:

insights from single-cell analysis. *Nat Rev Cancer*. 2020;20(4):218–232.

36. Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in

colorectal cancer. *Nature*. 2018;564(7735):268–272.

37. Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non-small-cell lung

cancer by single-cell sequencing. *Nat Med*. 2018;24(7):978–985.

38. Clarke J, Panwar B, Madrigal A, et al. Single-cell transcriptomic analysis of tissue-resident

memory T cells in human lung cancer. *J Exp Med*. 2019;216(9):2128–2149.

39. Szabo PA, Miron M, Farber DL. Location, location, location: Tissue resident memory T cells

in mice and humans. *Sci Immunol*. 2019;4(34):eaas9673.

40. Kok L, Masopust D, Schumacher TN. The precursors of CD8+ tissue resident memory T

cells: from lymphoid organs to infected tissues. *Nat Rev Immunol*. 2022;22(5):283–293.

41. Li H, van der Leun AM, Yofe I, et al. Dysfunctional CD8 T Cells Form a Proliferative,

Dynamically Regulated Compartment within Human Melanoma. *Cell*. 2019;176(4):775-

789.e18.

42. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of

adults with systemic lupus erythematosus reveal distinct type I and type II interferon

signatures. *Arthritis Rheumatol*. 2014;66(6):1583–1595.

43. Batlle E, Massagué J. Transforming Growth Factor-β Signaling in Immunity and Cancer.

Immunity. 2019;50(4):924–940.

44. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell

differentiation. *Nat Rev Immunol*. 2012;12(11):749–761.

45. Aibar S, González-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network

inference and clustering. *Nat Methods*. 2017;14(11):1083–1086.

46. Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The Evolving Role of CD8+CD28–

Immunosenescent T Cells in Cancer Immunology. *International Journal of Molecular*

Sciences. 2019;20(11):2810.

47. Tae Yu H, Youn J-C, Lee J, et al. Characterization of CD8(+)CD57(+) T cells in patients

with acute myocardial infarction. *Cell Mol Immunol*. 2015;12(4):466–473.

48. Le Priol Y, Puthier D, Lécureuil C, et al. High cytotoxic and specific migratory potencies of

senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. *J Immunol*.

2006;177(8):5145–5154.

49. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their

role in health and disease. *Immunology*. 2011;134(1):17–32.

50. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative

senescence and antigen-induced apoptotic death of CD8+ T cells. *Blood*. 2003;101(7):2711–

2720.

51. Pangrazzi L, Reidla J, Carmona Arana JA, et al. CD28 and CD57 define four populations

with distinct phenotypic properties within human CD8+ T cells. *Eur J Immunol*.

2020;50(3):363–379.

52. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of

clonal T-cell expansions in Myelodysplastic Syndrome. *Leukemia*. 2007;21(4):659–667.

53. Yoon SH, Yun SO, Park JY, et al. Selective addition of CXCR3+CCR4-CD4+ Th1 cells

enhances generation of cytotoxic T cells by dendritic cells in vitro. *Exp Mol Med*.

2009;41(3):161–170.

54. Groom JR, Luster AD. CXCR3 in T cell function. *Exp Cell Res*. 2011;317(5):620–631.

55. Maurice NJ, McElrath MJ, Andersen-Nissen E, Frahm N, Prlic M. CXCR3 enables

recruitment and site-specific bystander activation of memory CD8+ T cells. *Nat Commun*.

2019;10(1):4987.

56. van der Voort R, Brandao C, Volman TJ, et al. CXCR3 Is Required for the Efficient

Recruitment of Bone Marrow-Resident Memory T Cells to Inflamed Tissues,. *Blood*.

2011;118(21):3242.

538 57. Kurachi M, Kurachi J, Suenaga F, et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. *J Exp Med*. 2011;208(8):1605–1620.

541 58. Hu JK, Kagari T, Clingan JM, Matloubian M. Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. *Proceedings of the National Academy of Sciences*. 2011;108(21):E118–E127.

544 59. Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. *Nat Med*. 2019;25(8):1251–1259.

546 60. Lamprianidou E, Kordella C, Kazachenka A, et al. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3– T cells represents a potential antitumor mechanism of azacitidine. *Blood Adv*. 2021;5(1):129–142.

549 61. Gang AO, Frøsig TM, Brimnes MK, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. *Blood Cancer J*. 2014;4(3):e197.

552 62. Costantini B, Kordasti SY, Kulasekararaj AG, et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. *Haematologica*. 2013;98(8):1196–1205.

555 63. Zeidan AM, Fenaux P, Gobbi M, et al. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. *Blood*. 2022;140(3):285–289.

558 64. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424–447.

65. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously
Untreated Acute Myeloid Leukemia. *New England Journal of Medicine*. 2020;383(7):617–
629.

66. Rutella S, Vadakekolathu J, Mazziotta F, et al. Immune dysfunction signatures predict
outcomes and define checkpoint blockade–unresponsive microenvironments in acute
myeloid leukemia. *J Clin Invest*. 2022;132(21):.

67. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor
evasion of immune surveillance. *Cancer Cell*. 2005;8(5):369–380.

68. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk
Myelodysplastic Syndromes. *New England Journal of Medicine*. 2020;382(2):140–151.

69. Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in
myelodysplastic syndromes and primary myelofibrosis. *Blood*. 2019;133(8):790–794.

70. Platzbecker U, Santini V, Komrokji RS, et al. Analysis of Duration of Response, Exposure-
Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with
Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the
MEDALIST Study. *Blood*. 2021;138(Supplement 1):1524.

71. Overacre-Delgoffe AE, Chikina M, Dadey RE, et al. Interferon-γ Drives Treg Fragility to
Promote Anti-tumor Immunity. *Cell*. 2017;169(6):1130-1141.e11.

72. Boukhaled GM, Harding S, Brooks DG. Opposing Roles of Type I Interferons in Cancer
Immunity. *Annu Rev Pathol*. 2021;16:167–198.

73. Am G, Cj W, Daa V. Interferon-γ: teammate or opponent in the tumour microenvironment?
Nature reviews. Immunology. 2022;22(3):.

74. Yano S, Ghosh P, Kusaba H, Buchholz M, Longo DL. Effect of Promoter Methylation on the

Regulation of IFN-γ Gene During In Vitro Differentiation of Human Peripheral Blood T

Cells into a Th2 Population. *The Journal of Immunology*. 2003;171(5):2510–2516.

75. Ohtani H, Ørskov AD, Helbo AS, et al. Activation of a Subset of Evolutionarily Young

Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-

Azacytidine. *Cancer Research*. 2020;80(12):2441–2450.

76. Stone ML, Chiappinelli KB, Li H, et al. Epigenetic therapy activates type I interferon

signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Proceedings of the National Academy of Sciences. 2017;114(51):E10981–E10990.

77. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an

interferon response in cancer via dsRNA including endogenous retroviruses. *Cell*.

2015;162(5):974–986.

78. Wolff F, Leisch M, Greil R, Risch A, Pleyer L. The double-edged sword of (re)expression of

genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for

targeted immune checkpoint modulation. *Cell Commun Signal*. 2017;15(1):13.

79. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced

Melanoma. *N Engl J Med*. 2015;372(26):2521–2532.

80. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined

Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2019;381(16):1535–

1546.

81. Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of

Pembrolizumab in Patients With Metastatic Melanoma. *JCO*. 2018;36(17):1668–1674.

Table 1. Baseline patient characteristics

82. Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune

checkpoint inhibitors with chemotherapy in solid tumors. *Annals of Oncology*.

2019;30(2):219–235.

83. Miller BC, Sen DR, Al Abosy R, et al. Subsets of exhausted CD8+ T cells differentially

mediate tumor control and respond to checkpoint blockade. *Nat Immunol*. 2019;20(3):326–

336.

84. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T Cell States Associated with

Response to Checkpoint Immunotherapy in Melanoma. *Cell*. 2018;175(4):998-1013.e20.

85. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic

melanoma by single-cell RNA-seq. *Science (New York, N.Y.)*. 2016;352(6282):189.

86. Shallis RM, Bewersdorf JP, Gowda L, et al. Immune Checkpoint Inhibitor Therapy for

Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center

Experience. *Blood*. 2019;134(Supplement_1):1330.

87. Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in

myelodysplastic syndromes and acute myeloid leukemia. *Experimental Hematology &*

Oncology. 2022;11(1):11.

88. Mitroulis I, Tasis A, Grigoriou M, et al. Phenotypic and Molecular Landscape of Bone

Marrow CD8+ T Cells in Myeloid Neoplasms Predicts Response to Treatment with

Hypomethylating Agents. *Blood*. 2023;142(Supplement 1):4588.

Total No of patients, N	104

Age at diagnosis, N (%)	
>65yo	77 (74%)
<65yo	22 (21,2%)
N/A	5 (4,8%)

Sex, N (%)	
Male	69 (66.35%)
Female	35 (33.65%)

WHO classification, N (%)	
MDS-LB	19 (18.3%)
MDS-IB1	15 (14.4%)
MDS-IB2	26 (25.0%)
AML	32 (30.8%)
CMML-2	12 (11.5%)

Baseline blood counts, median (range)	
Hemoglobin (g/dL)	9.4 (5.4-14)
Absolute neutrophil count; ANC ($\times 10^9$/L)	2.01 (0-60)
Platelet count ($\times 10^9$/L)	90.5 (5-463)

(%) Bone marrow blasts, N (%)	
<5%	17 (16,4%)
5-10%	20 (19.2%)
11-20%	30 (28,85%)
>20%	30 (28,85%)
N/A	7 (6,7%)

Cytogenetic risk score (IPSS-R), N (%)	
Very good	3 (2,9%)
Good	57 (54,8%)

Intermediate	25 (24%)
Poor	2 (1,9%)
Very poor	9 (8,7%)
N/A	8 (7,7%)

Number of completed AZA cycles, median (range)

HR-MDS	9 (1-59)
AML	7(1-70)
CMML-II	7 (3-36)

IPSS-R, N (%)

Very low	4 (4.2%)
Low	8 (8.3%)
Intermediate	13 (13.6%)
High	30 (31.2%)
Very high	41 (42.7%)

IPSS-M, N (%)

Very low	5 (5.2%)
Low	13 (13.6%)
Moderate low	5 (5.2%)
Moderate high	8 (8.3%)
High	21 (21.9%)
Very high	44 (45.8%)

623 **Figure Legends**

Figure 1. Untargeted analysis of CD45[+] immune cells in patients with MDS, AML and CMML by CyTOF. (**A**) Multidimensional scale plot depicting the relationship between bone marrow (BM) samples of patients with LR-MDS (n=12), HR-MDS (n=15), AML (n=16) and CMML (n=5). (**B**) UMAP displaying the major immune cell clusters. (**C**) Heatmap showing the expression of the markers used for the characterization of each cell cluster. (**D**) Box charts displaying the frequency of each cell cluster. (**E**) Violin plots showing the expression level of CXCR3 in the CD8 T1, CD8 T2 and CD4 T2 clusters, respectively. Kruskal Wallis followed by "two-stage" Benjamini, Krieger & Yekutieli multiple comparison test was used in D. One-way ANOVA followed by "two-stage" Benjamini, Krieger & Yekutieli multiple comparison test was used in E. *p < 0.05, **p < 0.01.

Figure 2. Identification of a CD8[+] subpopulation (CD57[+]CXCR3[+]) which distinguishes MDS patients from AML and CMML patients. (**A**) Representative viSNE plots, derived from the FlowSOM analysis of BM CD8[+] T cells from patients with LR-MDS (n=12), HR-MDS (n=15), AML (n=16) and CMML (n=5). (**B**) Bar plots displaying the proportion of the metaclusters between the groups, expressed as percentage within CD8[+] T cells. (**C**) Heatmap depicting the expression level of the T-related markers between the metaclusters. (**D**) Violin plots showing the expression level of CXCR3 in metacluster 1. (**E**) Representative flow cytometry plots for the identification of the CD57[+]CXCR3[+] CD8[+] T cell subpopulation in a cohort of patients with LR-MDS (n=7), HR-MDS (n=27), AML (n=20) and CMML (n=10). (**F**) Percentage of CD57[+]CXCR3[+] cells within CD8[+] T cells. Kruskal Wallis was used in B and D.

646 One-way ANOVA followed by "two-stage" Benjamini, Krieger, & Yekutieli multiple

647 comparison test was used in F. *p< 0.05, **p < 0.01, ***p < 0.001.

Figure 3. Association between the frequency of CD57⁺CXCR3⁺CD8+ and outcome in

patients with HR-MDS and AML under treatment with AZA. (**A**) Box plots displaying the

percentage of the CD57⁺CXCR3⁺ cells within CD8+ T cells, assessed by flow cytometry in

responders and non-responders (HR-MDS, n=12 Responders and 9 Non-Responders; AML, n=9

Responders and 11 Non-Responders; CMML, n=5 Responders and 5 Non-Responders). (**B**)

After stratification of HR-MDS and AML patients to responders (n=12) and non-responders

(n=19), FlowSOM analysis was performed on BM CD8⁺ T cells, which generated 6 metaclusters

that are projected onto the viSNE plots. Representative viSNE plots (one for each group) are

shown. (**C**) Heatmap depicting the expression levels of all T-related markers (**D**) Box plots

showing the proportion of all metaclusters, expressed as frequency within CD8⁺ T cells. (**E**)

Kaplan Meier curves for overall survival (OS) in patients which received AZA treatment, with

≤29% (n=51) and >29% (n=26) CD57⁺CXCR3⁺ CD8⁺ T cells before treatment initiation. The

survival curves were compared by Log-rank (Mantel-Cox) test and the p value is shown. Median

OS of the ≤29% group was 20.98 months, while the median OS of the >29% group was 12.05

months. (**F**) Survival curves for each disease subgroup. Increased (%) CD57⁺CXCR3⁺ correlates

significantly with worse survival in HR-MDS and AML patients, whereas no association is

observed in CMML patients. (**G**) HR-MDS and AML patients with ≤29% CD57⁺CXCR3⁺

exhibited higher response rates. No association between the frequency of CD57⁺CXCR3⁺ CD8⁺

T cells and response to therapy was observed in CMML patients. Unpaired Student's t test was

used in A**.** Mann-Whitney U test was used in D. *p < 0.05, **p < 0.01, ***p < 0.001.

Figure 4. Profiling of BM-derived CD8$^+$ T cells of HR-MDS and AML patients with

scRNA-seq. (**A**) Uniform Manifold Approximation and Projection (UMAP) of CD8$^+$ T cells

identified 11 clusters. A total of 28,449 CD8$^+$ T cells were pooled from 4 HR-MDS (15,597

cells) and 5 AML patients (12,852 cells). (**B**) Bubble plot depicting the average expression of

genes used to characterize the clusters. (**C**) Expression of selected genes projected onto UMAPs.

(**D**) Heatmap showing selected top differentially expressed genes for each cell cluster. (**E**)

Ridgeline plots displaying the cytotoxic signature score for each cell cluster, as defined by the

expression of key-related genes. (**F**) Ridgeline plots displaying the cell cycle signature score for

each cell cluster. Differential expression data are reported in Data sheet 1. (G) UMAP

visualization of trajectories colored by pseudotime.

Figure 5. BM-derived CD8$^+$ T cells from responders (CR) to AZA show an enhanced ISG

molecular signature compared to non-responders (FAIL) in scRNAseq analysis. (**A**)

Comparison of separate UMAPs for CR (a total of 13,667 cells, 7,571 from MDS and 6,096 cells

from AML patients, respectively) and FAIL patients (a total of 14,782 cells, 8,026 cells from

MDS and 6,756 cells from AML patients, respectively). (**B**) Stacked bar chart showing the

average distribution of clusters between the two groups. The percentage of cluster 10

(Proliferative) was increased in CR compared to FAIL patients (Unpaired Student's t test,

p=0.0418). (**C**) Dot plot representing MSigDB (Hallmark 2020) enrichment analysis of

positively enriched pathways in CR patients. Enriched pathways with a q-value <0.05

(Benjamini-Hochberg correction) are shown. (**D**) Gradient expression of representative selected

genes involved in IFN-related pathways, as they are projected onto UMAPs. (**E**) ISG (Interferon

Stimulated Genes) score of cluster 0 (*GZMK*) and violin plots showing the expression levels of

the top differentially expressed IFN-stimulated genes of cluster 0 (*GZMK*) between CR and

FAIL. (**F**) ISG score of cluster 1 (*EOMES*) and violin plots showing the expression levels of the

top differentially expressed IFN-stimulated genes of cluster 1 (*EOMES*) between CR and FAIL.

(**G**) ISG score of cluster 2 (CTL_1) and violin plots displaying the expression levels of the top

differentially expressed IFN-stimulated genes of cluster 2 (CTL_1) between CR and FAIL. (**H**)

ISG score of cluster 4 (CTL_2) and violin plots displaying the expression levels of the top

differentially expressed IFN-related genes of cluster 4 (CTL_2) between CR and FAIL.

Differential expression data are reported in Data sheet 2.

Figure 6. BM-derived CD8$^+$ T cells of non-responders (FAIL) displayed suppressed cytotoxic molecular signature at the single-cell level. (**A**) Dot plot representing MSigDB (Hallmark 2020) enrichment analysis of positively enriched pathways in FAIL patients. Enriched pathways with a q-value <0.05 (Benjamini-Hochberg correction) are shown. (**B**) TGF-β signaling score of cluster 2 (CTL_1) and violin plots displaying the expression levels of the top differentially expressed genes of cluster 2 (CTL_1), involved in the enrichment of the TGF-β signaling pathway between CR and FAIL. (**C**) TGF-β signaling score of cluster 4 (CTL_2) and violin plots displaying the expression levels of the top differentially expressed genes of cluster 4 (CTL_2), involved in the enrichment of the TGF-β signaling pathway between CR and FAIL. (**D**) Comparison of the cytotoxic score of each group, as it is projected onto the respective UMAPs. (**E**) Cytotoxic score of cluster 2 (CTL_1) and violin plots exhibiting the expression levels of the top differentially expressed cytotoxicity-related genes of cluster 2 (CTL_1) between CR and FAIL. (**F**) Cytotoxic score of cluster 4 (CTL_2) and violin plots exhibiting the

expression levels of the top differentially expressed cytotoxicity-related genes of cluster 4

(CTL_2) between CR and FAIL. Differential expression data are reported in Data sheet 2.

Figure 7. Transcription Factor (TF) regulatory network analysis in BM-derived CD8$^+$ T

cells. (**A**) UMAP depicting the clustering of CD8$^+$ T cells based on regulons. (**B**) Pie charts

illustrating the representation of cells from CR and FAIL patients within each regulon. (**C**)

Comparison of cell distribution in regulons between the groups utilizing separate UMAPS for

each group. (**D**) Heatmap showing the top differentially activated TFs of each regulon-cluster.

(**E-F**) Violin plots depicting the activity score of selected TFs per sample type in regulons 5 and

7, respectively.